Literature DB >> 26195059

The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.

Bhupendra O Khatri1, Jeffery Garland2, Joseph Berger3, John Kramer4, Lisa Sershon5, Tayo Olapo6, Jean Sesing7, Mary Dukic8, Eileen Rehn9.   

Abstract

Dimethyl fumarate (Tecfidera™) is an effective therapy for relapsing forms of multiple sclerosis (MS). Our study suggests that this drug may have immunosuppressive properties evidenced by significant sustained reduction in CD8 lymphocyte counts and, to a lesser extent, CD4 lymphocyte counts. This observation is relevant in light of the recent case of progressive multifocal leukoencephalopathy in a patient receiving this drug.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Lymphocyte counts; PML; RRMS

Mesh:

Substances:

Year:  2015        PMID: 26195059     DOI: 10.1016/j.msard.2015.05.003

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  22 in total

1.  Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.

Authors:  Charlotte Rastas; David Sirignano; Amanda Barner; Lou Ann Bruno-Murtha
Journal:  J Neurol       Date:  2019-07-26       Impact factor: 4.849

Review 2.  Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis.

Authors:  Elena Grebenciucova; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08       Impact factor: 5.081

Review 3.  Multiple sclerosis: Dimethyl fumarate is coming of age.

Authors:  Mar Tintoré; Jaume Sastre-Garriga
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

Review 4.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 5.  Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Elena Grebenciucova; Amy Pruitt
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-22       Impact factor: 5.081

6.  Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.

Authors:  Lana Zhovtis Ryerson; Rivka Green; Gladyne Confident; Krupa Pandey; Benjamin Richter; Tamar Bacon; Carrie Sammarco; Lisa Laing; Jennifer Kalina; Ilya Kister
Journal:  Ther Adv Neurol Disord       Date:  2016-08-04       Impact factor: 6.570

7.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

Review 8.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

Review 9.  Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.

Authors:  Harald Hegen; Michael Auer; Florian Deisenhammer
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

10.  Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy.

Authors:  Dhanashri P Miskin; Susan T Herman; Long H Ngo; Igor J Koralnik
Journal:  J Neurovirol       Date:  2015-12-16       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.